Peripheral T-cell Lymphoma

So, it could be cd8+ aggressive primary cutaneous tcl, could be a gamma/delta tcl, could still be an alcl, need to perform cd30, or could be a peripheral tcl. (@et565)

Dr. @ravivij Discussing with @NehaMehtaShahMD on #pheripheral #tcell #lymphoma (PTCL) at @My_Cancer_Haven Thank You So much for your support @NehaMehtaShahMD 😊🙏 Get Full Access to the Video, by Signing Up at https://t.co/XIinFH8pLB https://t.co/nnm8ehgnlj (@My_Cancer_Haven)

The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities and led to early indications of efficacy in patients with relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. @CwynKate @uclh @icmlugano #ICML17 #lymsm #oncology https://t.co/NG8LThxMqe (@OncLive)

Findings from the AUTO4-TL1 trial demonstrated that AUTO4 showed early clinical activity and tolerability in relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. @CwynKate @uclh @icmlugano #ICML17 #lymsm #oncology https://t.co/witNC7xJW1 (@OncLive)

Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/v5J1uSXhsl (@OncLive)

Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/TJCxD8CBUh (@OncLive)

Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/vb4qA0I7UF (@OncLive)

#17ICML @CwynKate describes the clinical findings of AUTO4, a CAR T-cell product targeting TRBC1 for patients with TRBC1-positive PTCL. Follow-up data show AUTO4 was well tolerated without dose limiting toxicity. The study is ongoing to define phase 2 dose #lymsm #leusm #lymphoma (@lymphomahub)

Camus et al - 5y FU Ro-CHOP in PTCL • overall no benefit RoCHOP v CHOP • possible benefit in Tfh • many diff regimens at relapse • v poor PFS2 & OS2 • poss benefit of BV-cont regimens at relapse Great @LysaLymphoma study #17ICML (@graham74GC)

Hot off the press! PTCL review authored by all @WomenInLymphoma. Just one of several WiL reviews released in conjunction with #17ICML (@DrJulieVose)

CHOP-X could be a good start to target PTCL based on the genomic profiling, a one size fits all does not for this lymphoma #lymsm #17icml https://t.co/DAPnxbSCuD (@HayderSaeed_MD)

How to treat Peripheral T-cell lymphoma. Feat; PL Zinzani @icmlugano #ICML2023 (@j_marquet)

Educational session about current and future directions in peripheral T-cell lymphomas therapeutic approach By prof PL Zinzani #17ICML (@Fer_martinmoro)

Pier Luigi Zinzani: Cautionary Note, No RCTs for Upfront ASCT in PTCL, risk of overtreatment. #17ICML #lymsm @icmlugano @LymphomaEx (@iHematologo)

@CwynKate your Abstract has been posted online FIRST IN HUMAN STUDY OF AUTO4, A TRBC1-TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1-POSITIVE PERIPHERAL T-CELL LYMPHOMA https://t.co/39iw2Q56AN (@DmitryKovalchuk)

Final results of a multicenter phase II trial of lenalidomide plus CHOEP in untreated PTCL: moderate response rates with considerable haematologic toxicity https://t.co/jdWbhm0r1v #lymsm @lymphomaphilia @NicolaisRobert @DrJulieVose @NehaMehtaShahMD @luuqpham @BradHaverkos (@BrJHaem)

"A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant" At #ASCO23 from 2 @WUHemeOncFellow --Niki Foley and soon-to-be @WashUOnc faculty @dgermain21 #lymsm https://t.co/y4Bcx859ZP (@WashUOnc)

#Hematology Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell #lymphoma #PTCL | ⁦@BloodJournal⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm #hemepath https://t.co/Blfn3R510Q (@DrRaulCordoba)

Excellent summary from #SteveHorwitz: Frontline Rx of PTCL: Ro-CHOP: impressive @LysaLymphoma randomised Ph 3 (but designed before biological insights) @BachyEmmanuel & present 🇺🇸 Alliance Randomised Ph 2 trial in CD30- PTCL: CHO(E)P +/- Duvelisib vs CC-486 CI #NehaMehtaShah (@CwynKate)

⁦@Hememachine⁩ on ICC classification: ALK-neg ALCL: DUSP22: helping inform our discussions on whether to perform #ASCT in #PTCL in 1st response? Important randomised French TRANSCRIPT Trial ongoing ⁦⁦@LysaLymphoma⁩ ⁦@BachyEmmanuel⁩ #lymsm (@CwynKate)

Which subtype if T cell lymphoma . . . Presuming PTCL-NOS since CD30 neg ? (@timfenske)

🔬PERIPHERAL T-CELL LYMPHOMA WITH T FOLLICULAR HELPER (TFH) CELL PHENOTYPE. ICOS is strongly positive (below), together with PD1 and BCL6 positivity there is good evidence for TFH phenotype. Thank you for all the help on this case!🙏🏆 (@JacobSmalberger)

cerdulatinib ⊣ {Syk, JAK1, JAK3} inhibitor of the JAK/STAT pathway on trial for peripheral T cell lymphoma "Jack is a CERvile aDULATIng Sykophant" #mnemonic 日本語話者はJAKと1と3で「ジャッキーさん is...」と覚えるとなお良ス #語呂合わせ new piece of knowledge I got at #USCAP2022 (@mona8schmona)

Hard to say w/o images. Do U have flow (is CD3 both surface and cyto?) still want to see other T cell markers: TCRB, TCR GD, TIA, granzyme also CD34, TdT. Could still be a mature T cell lymphoma like hepatosplenic which fits better w/ the presentation. karyotype? Look for i(7q) (@sanamloghavi)

Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Patients/ Patients w/ Significant Comorbidities Ineligible for Standard Chemo @DrAEvens https://t.co/uNDgN0Yjbf (@RutgersCancer)

BBv in R/R #PTCL (Retrospect, multi center). Not all CD30+. ORR 70%. 51% CR. As expected IPI, responders, and those who had transplant had better PFS/OS. AE: Cytopenias #ASH21 #Lymphoma (@AlhajMoustafa)

Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Pts or Pts w/ Significant Comorbidities Ineligible for Standard Chemo https://t.co/8b3Xew0H54 @DrAEvens (@RutgersCancer)

Anaplastic Large Cell Lymphoma! Peripheral T-cell lymphoma Pathology CD30+ Hallmark cell ALK+ = good prognosis ALK- = worse prognosis ALK- but DUSP22+ = better prognosis? ALK-TP63+ = bad prognosis Rx = BV+CHP No ASCT in CR1 for ALK+ Roll of ASCT in CR1 for ALK- is unclear (@AaronGoodman33)

A nice study in PTCL with an awesome RCT planned for CD30 negative disease! #ASH21 Paper: High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis https://t.co/iHpSxtyAlQ (@AaronGoodman33)

Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Pts or Pts w/ Significant Comorbidities Ineligible for Standard Chemo https://t.co/uNDgN0Yjbf @DrAEvens (@RutgersCancer)

CD30 expression in lymphoma 100% of time Hodgkin lymphoma Systemic anaplastic large cell lymphoma (Both ALK-/+) Primary cutaneous ALCL Lymphomatoid papulosis Sometimes DLBCL PTCL, NOS Angioimmunoblastic Mycosis fungoides (more often with large cell transformation) (@AaronGoodman33)

Clinic Today for the General Malignant Hematologist R/R DLBCL getting CART soon PMBCL Myeloma post ASCT Mantle cell lymphoma presenting with HLH (yes really) Myelofibrosis in need of allo Hemochromatosis AML FT3 ITD low/NPM1+ in CR PTCL Myeloma on BiTE Rx trial HSTCL post allo (@AaronGoodman33)

GATA3 narrows it down to T cell lymphoma vs bladder ca vs breast ca. The eosinophils make me favor T cell lymphoma. Maybe ALCL? Don't know if ALCL stains for GATA3, I know about half of PTCL,NOS stains for it. (@debpratik)

GM #lymsm #lymphoma peeps. Need help with a case. 67 yo M with sIV PTCL-NOS (CD30+;RS like-cells; EBER and HTLV -) who progressed after 3 cycles of CHOP with 5 brain lesions. Tx recs? 🤔@guiperini @DunleavyKieron @bpromd @graham74GC @HayderSaeed_MD @DrAnasYounes. Thanks! (@HemSandoval)

Thank u so much for your help ..so the diffuse CD30 expression favour anaplastic ALK neg if HOdgkins is excluded.. I mean CD30 positive PTCL,NOS usually don't show that diffuse pattern ..🤔 (@Dramanyhassany1)

(1/3) 60y F axillary lymphadenopathy .. #hemepath did you encounter CD15 positive cells in ALK negative ALCL or this may be PTCL NOS with expression of CD30 and CD15 @mjcascio @SibaElHussein @sanamloghavi @KMirza @evemariecrane @doctorpemm @GeronimoJrLapac (@Dramanyhassany1)